PFG Investments LLC Raises Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

PFG Investments LLC raised its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 37.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,750 shares of the biotechnology company’s stock after buying an additional 7,900 shares during the period. PFG Investments LLC’s holdings in Aurinia Pharmaceuticals were worth $164,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. HighMark Wealth Management LLC boosted its holdings in shares of Aurinia Pharmaceuticals by 3.0% during the first quarter. HighMark Wealth Management LLC now owns 75,196 shares of the biotechnology company’s stock worth $377,000 after purchasing an additional 2,197 shares during the period. ProShare Advisors LLC lifted its holdings in Aurinia Pharmaceuticals by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 34,464 shares of the biotechnology company’s stock worth $173,000 after buying an additional 2,873 shares during the period. Vermillion & White Wealth Management Group LLC bought a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter worth approximately $30,000. Tidemark LLC purchased a new position in shares of Aurinia Pharmaceuticals during the fourth quarter valued at approximately $39,000. Finally, Hennion & Walsh Asset Management Inc. raised its holdings in shares of Aurinia Pharmaceuticals by 7.1% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 75,787 shares of the biotechnology company’s stock valued at $380,000 after acquiring an additional 5,043 shares in the last quarter. 36.83% of the stock is owned by institutional investors.

Aurinia Pharmaceuticals Trading Up 6.8 %

Shares of NASDAQ AUPH opened at $7.03 on Friday. The stock has a market cap of $1.01 billion, a P/E ratio of -16.35 and a beta of 1.44. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.33 and a quick ratio of 4.82. Aurinia Pharmaceuticals Inc. has a 1 year low of $4.71 and a 1 year high of $10.05. The firm has a 50-day moving average of $6.06 and a 200 day moving average of $5.55.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings results on Thursday, August 1st. The biotechnology company reported $0.01 EPS for the quarter, hitting analysts’ consensus estimates of $0.01. Aurinia Pharmaceuticals had a negative return on equity of 11.84% and a negative net margin of 24.31%. The firm had revenue of $57.10 million for the quarter, compared to analysts’ expectations of $54.25 million. During the same period in the previous year, the firm posted ($0.08) EPS. The business’s revenue for the quarter was up 37.6% compared to the same quarter last year. As a group, sell-side analysts expect that Aurinia Pharmaceuticals Inc. will post 0.13 EPS for the current fiscal year.

Insider Activity

In related news, insider Scott Michael Habig sold 18,249 shares of the stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $5.31, for a total transaction of $96,902.19. Following the sale, the insider now directly owns 456,338 shares of the company’s stock, valued at approximately $2,423,154.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.30% of the company’s stock.

Analysts Set New Price Targets

AUPH has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $13.00 price target on shares of Aurinia Pharmaceuticals in a report on Friday, September 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $10.00 target price on shares of Aurinia Pharmaceuticals in a research note on Monday, September 9th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $10.00.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.